- Home
- KUKE vs INAB Comparison
KUKE vs INAB Comparison
Compare KUKE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- INAB
- Stock Information
- Founded
- KUKE 2002
- INAB 2016
- Country
- KUKE China
- INAB United States
- Employees
- KUKE N/A
- INAB N/A
- Industry
- KUKE Other Consumer Services
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- INAB Health Care
- Exchange
- KUKE Nasdaq
- INAB Nasdaq
- Market Cap
- KUKE 21.2M
- INAB 24.0M
- IPO Year
- KUKE 2021
- INAB 2021
- Fundamental
- Price
- KUKE $0.33
- INAB $0.27
- Analyst Decision
- KUKE
- INAB Strong Buy
- Analyst Count
- KUKE 0
- INAB 3
- Target Price
- KUKE N/A
- INAB $7.75
- AVG Volume (30 Days)
- KUKE 124.2K
- INAB 677.0K
- Earning Date
- KUKE 12-31-2024
- INAB 11-12-2024
- Dividend Yield
- KUKE N/A
- INAB N/A
- EPS Growth
- KUKE N/A
- INAB N/A
- EPS
- KUKE N/A
- INAB N/A
- Revenue
- KUKE $14,784,158.00
- INAB N/A
- Revenue This Year
- KUKE N/A
- INAB N/A
- Revenue Next Year
- KUKE N/A
- INAB N/A
- P/E Ratio
- KUKE N/A
- INAB N/A
- Revenue Growth
- KUKE 10.48
- INAB N/A
- 52 Week Low
- KUKE $0.23
- INAB $0.22
- 52 Week High
- KUKE $4.07
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- KUKE 41.48
- INAB 41.66
- Support Level
- KUKE $0.30
- INAB $0.28
- Resistance Level
- KUKE $0.37
- INAB $0.32
- Average True Range (ATR)
- KUKE 0.05
- INAB 0.04
- MACD
- KUKE 0.01
- INAB -0.00
- Stochastic Oscillator
- KUKE 33.96
- INAB 0.00
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.